Bayrakli, FatihBalaban, HaticeOzum, UnalDuger, CevdetTopaktas, SuatKars, Hamit Zafer2019-07-272019-07-282019-07-272019-07-2820120940-6719https://dx.doi.org/10.1007/s00586-012-2319-7https://hdl.handle.net/20.500.12418/8947To investigate the effect of an anti-TNF-alpha agent (etanercept) on recovery processes in a partial spinal cord injury (SCI) model using clinical and electrophysiological tests. Twenty-four New Zealand rabbits were divided into three groups: group 1 [SCI + 2 ml saline intramuscular (i.m.), n = 8], group 2 (SCI + 2.5 mg/kg etanercept, i.m., 2-4 h after SCI, n = 8) and group 3 (SCI + 2.5 mg/kg etanercept, i.m., 12-24 h after SCI, n = 8). Rabbits were evaluated before SCI, immediately after SCI, 1 week after, and 2 weeks after SCI, clinically by Tarlov scale and electrophysiologically by SEP. Tarlov scores of groups 2 and 3 were significantly better than group 1, 2 weeks after SCI. SEP recovery was significantly better in groups 2 and 3 than group 1, 2 weeks after SCI. These results show that blocking TNF-alpha mediated inflammation pathway by an anti-TNF-alpha agent enhances clinical and electrophysiological recovery processes in partial SCI model.en10.1007/s00586-012-2319-7info:eu-repo/semantics/openAccessSpinal cord injuryInflammationTNF-alphaEtanerceptSomatosensory evoked potentialsArticle211225932588225267072-s2.0-84875726725Q1WOS:000311780000025Q2